Ushering in a New Class of Disease-Modifying DTx
A deep discussion on the science and engineering behind an emerging class of treatments that use novel neuro-physiology technologies to treat therapeutic targets that have proven undruggable for decades. A look at how these technologies can realize disease-modification for the first time in diseases like Alzheimer's, Cognitive decline, MS, and neuro-psychological conditions such as schizophrenia.
Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.
Nancy Isenberg
Swedish Neuroscience Institute
![photo of Eddie Martucci](/vite/assets/person-placeholder-edu-fS1N5G6a.png)
Eddie Martucci
Akili Interactive
![photo of Georgia Mitsi](/vite/assets/person-placeholder-edu-fS1N5G6a.png)
Georgia Mitsi
Biogen
![photo of Brent Vaughan](/vite/assets/person-placeholder-edu-fS1N5G6a.png)
Brent Vaughan
Cognito Therapeutics